Omid Hamid MD (@omidhamidmd) 's Twitter Profile
Omid Hamid MD

@omidhamidmd

Chief of Research and Immunotherapy • ImmunoOncology • Phase I Clinical Trials • Melanoma • Cutaneous Oncology

ID: 2171269956

linkhttp://www.theangelesclinic.org calendar_today03-11-2013 01:41:24

4,4K Tweet

4,4K Takipçi

810 Takip Edilen

Bastien Fachan (@bastienfachan) 's Twitter Profile Photo

Roger Federer’s Commencement Address at Dartmouth yesterday might be the best speech he’s ever given. Amazingly articulate, funny, full of wisdom. Made me laugh and tear up. I’m so very proud to have had him as my idol for the past two decades. If you have 25 minutes to spare…

Omid Hamid MD (@omidhamidmd) 's Twitter Profile Photo

Did you see this data Paolo A. Ascierto presents @BMS Realtivity048 ASCO PD-1/LAG3/CTLA4 with OS curve !! Once again melanoma pushes the boundaries.... currently accruing this regimen +/-sarilumab #ASCO24 The Angeles Clinic NYU Langone Health MassGeneral Medicine Dana-Farber ascopubs.org/doi/10.1200/JC…

Janice Mehnert, MD (@janicem10) 's Twitter Profile Photo

Listen to Omid Hamid MD, he's got the West Coast covered but Perlmutter Cancer Center at NYU Langone Health has this regimen +/sarilumab as a toxicity modulatory in New York City. State of the art regimen, but we are trying to improve it by making it less toxic. Our patients deserve no less.

Anthony El-Khoueiry (@drelkhoueiry) 's Twitter Profile Photo

Honored to have served as lead investigator on phase I study of botensilimab with expansion in MSS CRC; activity across cold tumors! Thank you to all co-authors and Agenus for the great collaboration. Gratitude to our amazing phase I team at USC Norris! nature.com/articles/s4159…

Omid Hamid MD (@omidhamidmd) 's Twitter Profile Photo

Appreciate ASCO The ASCO Post allowing me to discuss the future with Bispecific ImmTAC Immunocore #ASCO24 work done at many institutes including Cedars-Sinai The Angeles Clinic #Brenetefusp currently enrolling phase 3 trial for cutaneous #melanoma #ASCO24 ascopost.com/videos/2024-as…

Immunocore (@immunocore) 's Twitter Profile Photo

Despite its name, PRAME (or PReferentially expressed Antigen in #Melanoma) is common in multiple #cancers and is believed to play a role in tumor progression. Visit our Science page for more: immunocore.com/science #IMCRSharing

Despite its name, PRAME (or PReferentially expressed Antigen in #Melanoma) is common in multiple #cancers and is believed to play a role in tumor progression. 

Visit our Science page for more: immunocore.com/science

#IMCRSharing
KenOliveLab (@kenolivelab) 's Twitter Profile Photo

Stunning interim clinical trial data from Revolution Medicines... PFS = 8.1 mo in 2nd line KRAS G12-mutant metastatic #PDAC. OS not yet reached, but already more than a year! Benchmark PFS for this group is 2-3.5 months, behnchmark OS is 6.1-6.9. 1/

Stunning interim clinical trial data from Revolution Medicines... PFS = 8.1 mo in 2nd line KRAS G12-mutant metastatic #PDAC. OS not yet reached, but already more than a year! Benchmark PFS for this group is 2-3.5 months, behnchmark OS is 6.1-6.9.  1/
Targeted Oncology (@targetedonc) 's Twitter Profile Photo

In this episode of Targeted Talks, Omid Hamid, MD, (Omid Hamid MD) delves into the mechanism of action, supporting data, and approval of lifileucel for the treatment of advanced #melanoma. #MELSM | The Angeles Clinic targetedonc.com/view/advancing…

Melanoma Research Foundation (@curemelanoma) 's Twitter Profile Photo

We’ve been cheering on Sydney McLaughlin-Levrone as she competes in the Summer Olympics, and last week, she brought home the gold in the 400m hurdles! Sydney is not only a champion on the track but also a powerful advocate for skin protection. Partnering with Neutrogena, our National Prevention

Omid Hamid MD (@omidhamidmd) 's Twitter Profile Photo

Listen to your friends, your family, your doctor, and a gold medal Olympian. Sydney McLaughlin-Levrone. We continue to fight to stop melanoma and search for cures but the best option is prevention The Angeles Clinic #worktodo

Dr. Patrick Hwu (@patrickhwumd) 's Twitter Profile Photo

#ScienceSaturday The combination of anti-LAG-3 and anti-PD1 antibodies is U.S. FDA approved for patients with advanced #melanoma. But how is this combination working mechanistically? In a recent issue of Cell, 3 manuscripts shed light and suggest that PD-1 blockade

#ScienceSaturday 

The combination of anti-LAG-3 and anti-PD1 antibodies is <a href="/US_FDA/">U.S. FDA</a> approved for patients with advanced #melanoma. But how is this combination working mechanistically? In a recent issue of <a href="/CellCellPress/">Cell</a>, 3 manuscripts shed light and suggest that PD-1 blockade
Dr. Patrick Hwu (@patrickhwumd) 's Twitter Profile Photo

So sad to hear about the passing of Jeff Weber, a giant in the field of oncology. He was involved in the early days of cytokine and cell therapy and most recently led studies of personalized vaccines for melanoma patients. I originally worked with Jeff National Cancer Institute over 30 years ago.

So sad to hear about the passing of Jeff Weber, a giant in the field of oncology. He was involved in the early days of cytokine and cell therapy and most recently led studies of personalized vaccines for melanoma patients. I originally worked with Jeff <a href="/theNCI/">National Cancer Institute</a> over 30 years ago.
Omid Hamid MD (@omidhamidmd) 's Twitter Profile Photo

Jeff Weber's career was not only filled with patient advocacy, leadership and achievement but punctuated by mentorship. I urge all fellows and junior faculty to find someone like Jeff – great friend, amazing mentor, brother, leader.  Jeff was on a trial call this Thursday at 7

Jeff Weber's career was not only filled with patient advocacy, leadership and achievement but punctuated by mentorship.  I urge all fellows and junior faculty to find someone like Jeff – great friend, amazing mentor, brother, leader.  Jeff was on a trial call this Thursday at 7
Florentia Dimitriou, MD PhD PD (@fdimitrioumd) 's Twitter Profile Photo

🎉 🎉 Excited to share our latest research, now in Nature Cancer IrAEs can be associated with significant morbidity or mortality - our study suggests that targeting IL-17A CD4+ T cells could help manage these side effects better, and paves the way for 🎯 treatment approaches

Omid Hamid MD (@omidhamidmd) 's Twitter Profile Photo

Still reeling from the loss of Jeff Weber in our oncology Community. grateful for mentorship and programming especially the "Weber Rules" - there are 11 of 'em. My favorite is #11. "When all else fails, always talk to the patient." (yup) - more to come Hem-Onc Fellows Network ASCO

Omid Hamid MD (@omidhamidmd) 's Twitter Profile Photo

IBI363 PD-1/IL2α bispecific FDA Fast Track Designation for Advanced/Metastatic #Melanoma (DCR) 73.0%. Among 8 immuno-oncology (IO)–naive patients with #mucosalmelanoma, ORR was 75.0%, including 1 CR and 5 PRs. The DCR in this population was 100%. Innovent Melanoma Research Foundation